Fusobacterium naviforme

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Fusobacterium naviforme is a Gram-negative, non-spore-forming, strictly anaerobic, rod-shaped bacterium. It has been detected in at least 5 gut microbiome compilation studies or metastudies. Fusobacterium naviforme is probably a rare gut coloniser. (Gharbia2010aBergey)



  • This organism has been recovered from human faeces and lesion (exudate). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread (notes: human and animal pathogen). It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Gharbia2010aBergey);
    Character Response
  • 💧
  • Bile tolerance:
  • Doesn't tolerate bile
  • Active enzymes:
  • β-glucuronidase;
    • SPECIAL FEATURES (Gharbia2010aBergey);
    Character Response
  • ✗
  • Haemolysis:
  • absent
    • RESPONSE TO ANTIBIOTICS (Gharbia2010aBergey); (Goldstein2006c); (Goldstein2003a); (Schaumann1999); (Goldstein1999b);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; imipenem; meropenem; penicillin G; piperacillin-tazobactam;
  • Cephalosporins:
  • cefalexin; cefotaxime; cefuroxime;
  • Macrolides:
  • azithromycin; telithromycin;
  • clarithromycin; erythromycin; roxithromycin;
  • Tetracyclines:
  • doxycycline; tetracycline; tigecycline;
  • Quinolines:
  • gatifloxacin; moxifloxacin; trovafloxacin;
  • Heterocycles:
  • metronidazole;
  • Miscellaneous antibiotics:
  • clindamycin; telithromycin;

  • Holdeman, L. V., Good, I. J., & Moore, W. E. (1976). Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress. Applied and Environmental Microbiology, 31(3), 359–375.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Fusobacteria Class:  Fusobacteriia Order:  Fusobacteriales Family:  Fusobacteriaceae Genus:  Fusobacterium Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Morphology:  Rod
    Health:  Unknown
    Source:  human faeces and lesion (exudate)
    Bile reaction(%):  neg
    		Aesculin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Fructose:  neg Glucose:  neg Mannose:  neg Lactose:  neg Maltose:  neg Raffinose:  neg Sucrose:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  + AlkalineP:  neg AcidP:  neg Esterase(C4):  neg EstLip(C8):  neg Lipase:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.06, MIC90: 0.25, RNG: (≤0.015-0.5)
    penicillin_G:  S(MIC50): ≤0.03, MIC90: 0.125, RNG: (≤0.03-0.25)
    piper-taz:  S(MIC50): 0.03, MIC90: 0.125, RNG: (0.03–0.5)
    imipenem:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06-4)
    meropenem:  S(MIC50): 0.015, MIC90: 0.015, RNG: (0.015–0.03)
    cefalexin:  S(MIC50): 0.06, MIC90: 0.5, RNG: (≤0.03-1)
    cefotaxime:  S(MIC50): 0.125, MIC90: 8, RNG: (≤0.015->32)
    cefuroxime:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.03–1)
    azithromycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-1)
    erythromycin:  R(MIC50): 4, MIC90: 16, RNG: (0.25-16)
    clarithromycin:  R(MIC50): 8, MIC90: 32, RNG: (≤0.015-32)
    roxithromycin:  R(MIC50): 16, MIC90: >32, RNG: (2->32)
    telithromycin:  S(MIC50): 2, MIC90: 4, RNG: (≤0.015–8)
    ciprofloxacin:  Var(MIC50): 2, MIC90: 8, RNG: (≤0.5->8)
    gatifloxacin:  S(MIC50): 1, MIC90: 8, RNG: (0.06-8)
    levofloxacin:  Var(MIC50): 2, MIC90: >8, RNG: (0.25->8)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–2)
    trovafloxacin:  S(MIC50): 0.5, MIC90: 4, RNG: (0.25-4)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–1)
    tetracycline:  S(MIC50): 0.25, MIC90: 1, RNG: (≤0.03-2)
    tigecycline:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.03–0.125)
    metronidazole:  S(MIC50): 0.125, MIC90: 1, RNG: (≤0.03-2)
    clindamycin:  S(MIC50): ≤0.03, MIC90: ≤0.03, RNG: (≤0.03-0.06)

    References

    SPECIFIC REFERENCES FOR FUSOBACTERIUM NAVIFORME
  • Gharbia2010aBergey - Bergey's manual of systematic bacteriology. Vol. 4, The Fusobacteria. Family Fusobacteriaceae, Genus I. Fusobacterium
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • Schaumann1999 - In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR FUSOBACTERIUM NAVIFORME
  • Benno1986 - Comparison of the fecal microflora in rural Japanese and urban Canadians.
  • Dubourg2013 - The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Mangin2004 - Molecular inventory of faecal microflora in patients with Crohn's disease.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • Added: April 08, 2021